Approval · Notice of Compliance 35724 · 2025
BLENREP: Notice of Compliance 35724
Issued July 18, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35724
- Date
- July 18, 2025
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- BELANTAMAB MAFODOTIN 100 MG per VIAL
- BELANTAMAB MAFODOTIN 70 MG per VIAL